December 11, 2023 Mendus announces positive survival data from Phase 2 ADVANCE II trial evaluating vididencel as maintenance therapy for AML at ASH 2023 Read more
December 6, 2023 Toleranzia reports positive feedback from meeting with the Danish Medicines Agency Read more
December 6, 2023 Mendus and Australasian Leukaemia & Lymphoma Group to expand clinical testing of vididencel as maintenance treatment for AML Read more
November 21, 2023 Xspray Pharma’s XS003 Achieves Superior Bioavailability Milestone, Matching TASIGNA® at Reduced Dosage Read more
November 10, 2023 Egetis announces exclusive license agreement with Fujimoto to develop and commercialize Emcitate in Japan Read more
November 9, 2023 Xspray Pharma’s large shareholders and key individuals declare their intent to exercise TO5 warrants in November Read more
November 2, 2023 Prokarium Achieves Major Milestone with FDA’s IND Approval for Bladder Cancer Program Read more
October 17, 2023 Nanologica delivers silica to insulin manufacturer for evaluation in production Read more
October 16, 2023 KKR and Flerie Form Specialized Pharma Services Platform Frontier Biosolutions and Invest in Coriolis Pharma Read more
October 13, 2023 Xintela’s stem cell product, XSTEM, has been assessed as safe at all dose levels in knee osteoarthritis clinical study Read more
October 12, 2023 Synerkine Pharma secures €12.1 million to accelerate novel pain therapeutics towards clinical proof-of-concept Read more
October 11, 2023 Egetis Therapeutics has secured approximately SEK 462 million in a combined financing comprising a SEK 172 million equity private placement and SEK 290 million debt financing Read more
October 9, 2023 Egetis submits marketing authorisation application for Emcitate for treatment of MCT8 deficiency to the European Medicines Agency Read more
September 28, 2023 Geneos Therapeutics Closes its Series A3 Financing With Investment of $5 Million Read more
September 13, 2023 A3P Biomedical and BioAgilytix enter partnership for Stockholm3 in the USA Read more
September 11, 2023 Xspray Pharma and Bristol Myers Squibb Reach Settlement on Dasynoc™ Patent Litigation, Paving Way for Early Market Launch Read more
September 8, 2023 Mendus receives U.S. FDA Fast Track Designation for vididencel in Acute Myeloid Leukemia (AML) Read more
August 31, 2023 Stockholm3 combines accurate diagnosis of prostate cancer with improved health economics Read more
August 23, 2023 NorthX Biologics Welcomes Dr Janet Hoogstraate as New CEO Following Merger with Valneva Clinical Trials Manufacturing Unit Read more
August 22, 2023 Geneos Therapeutics Announces Eight of 34 Patients to Achieve Complete Response, Complete Molecular Response, or, Secondary Resectability in Ongoing Clinical Trial of Personalized Therapeutic Cancer Vaccination in Second Line Advanced Liver Cancer Read more
August 21, 2023 Toleranzia runs GMP manufacturing of drug candidate TOL2 for clinical study Read more
August 18, 2023 Toleranzia carries out a rights issue of units of approximately SEK 55 million Read more
August 17, 2023 AnaCardio receives IND approval from the FDA for AC01 to start a clinical pharmacology study Read more
August 16, 2023 Mendus publishes preclinical data demonstrating synergies of ilixadencel and 4-1BB-targeting immunotherapies Read more
July 28, 2023 Mendus raises approximately SEK 317 million through the directed issue to Flerie and a fully secured rights issue Read more
July 24, 2023 Egetis announces first patient included and second site activated in the pivotal ReTRIACt trial Read more
July 3, 2023 NorthX Biologics, a leading Nordic development and manufacturing organisation announces acquisition of a biologics manufacturing unit from Valneva Read more
June 8, 2023 Lipum has resolved on a rights issue of approximately SEK 26.4 million at a subscription price of SEK 9.20 per share Read more
June 8, 2023 Mendus announces a directed share issue and a fully secured rights issue of units totaling approximately SEK 317 million in financing Read more
June 8, 2023 Mendus and NorthX Biologics to enter into strategic cell therapy manufacturing alliance supported by new investor Flerie Read more
June 1, 2023 Xintela’s clinical study with XSTEM for knee osteoarthritis makes good progress Read more
June 1, 2023 Nanologica Delivers Silica to Latin-American Customer for Production of Insulin Read more
May 31, 2023 KAHR Reports Dose Escalation Results from Phase I Trial of DSP107 in Combination with anti-PD-L1 in Patients with Advanced Solid Tumors Read more
May 16, 2023 Strike Pharma and FyoniBio conclude successful cell line development of Strike’s bi-specific antibody and clinical lead candidate Read more
May 4, 2023 Stockholm3 included in American guidelines as a primary test for early detection of prostate cancer Read more
May 3, 2023 Empros Secures 80 MSEK Funding To Support Development Of Obesity Treatment Candidate – EMP16 Read more
May 2, 2023 Xspray announces a rights issue of units of approximately SEK 300 million ahead of Dasynoc product launch Read more
April 13, 2023 AnaCardio reports first patient dosed in the GOAL-HF1 study, a Phase 1b/2a Clinical Study in Heart Failure with AC01 in the EU and UK Read more
April 12, 2023 Microbiotica Announces Clinical Trial Collaboration with MSD to Evaluate MB097 in Combination with KEYTRUDA® (pembrolizumab) in a Phase 1b Clinical Trial in Melanoma Read more
March 23, 2023 Duke-NUS partners Alder Therapeutics to unleash the potential of cell-based regenerative therapy Read more
March 20, 2023 XNK receives certificate of GMP compliance of a manufacturer from the Medical Products Agency Read more
March 14, 2023 Ghrelin treatment in heart failure patients showed increased contractility of the heart Read more
February 23, 2023 Xspray Pharma Partners with EVERSANA for the U.S. Launch and Commercialization of its Lead Product, Dasynoc (XS004) for the Treatment of Chronic Myeloid Leukemia (CML) and Acute Lymphatic Leukemia (ALL) Read more
February 9, 2023 Prokarium Announces $30 Million Financing to Deliver Lead Program into Clinic and Build Novel Therapeutic Platform Read more
January 25, 2023 Atrogi announces first patient treated with its ATR-258 ß2 adrenoceptor agonist in a phase I clinical study for the treatment of type 2 diabetes Read more
January 17, 2023 Alder Therapeutics Licenses Two Cell Therapy Programs From DUKE-NUS and Biolamina Read more
